Cargando…

Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA

BACKGROUND: Intestinal permeability can be assessed by monitoring renal excretion of orally administered radioactively (51)Cr-labeled ethylenediaminetetraacetic acid ((51)Cr-EDTA). Although considered safe, patient participation in using radio-labeled tracers is low. Here, we used orally administere...

Descripción completa

Detalles Bibliográficos
Autores principales: von Martels, Julius Z. H., Bourgonje, Arno R., Harmsen, Hermie J. M., Faber, Klaas Nico, Dijkstra, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366711/
https://www.ncbi.nlm.nih.gov/pubmed/30730969
http://dx.doi.org/10.1371/journal.pone.0211973
_version_ 1783393649035313152
author von Martels, Julius Z. H.
Bourgonje, Arno R.
Harmsen, Hermie J. M.
Faber, Klaas Nico
Dijkstra, Gerard
author_facet von Martels, Julius Z. H.
Bourgonje, Arno R.
Harmsen, Hermie J. M.
Faber, Klaas Nico
Dijkstra, Gerard
author_sort von Martels, Julius Z. H.
collection PubMed
description BACKGROUND: Intestinal permeability can be assessed by monitoring renal excretion of orally administered radioactively (51)Cr-labeled ethylenediaminetetraacetic acid ((51)Cr-EDTA). Although considered safe, patient participation in using radio-labeled tracers is low. Here, we used orally administered (52)Cr-EDTA as non-radioactive alternative to assess intestinal permeability in CD and analyzed the association with disease activity, disease location and gut microbial dysbiosis. MATERIALS AND METHODS: 60 CD patients with low (n = 25) and increased (n = 35) fecal calprotectin levels (cut-off: 100 μg/g feces) ingested 20 mL (52)Cr-EDTA (20 mmol/L) solution whereafter 24-h urine was collected. Urinary (52)Cr-EDTA concentrations were quantified using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Fecal Enterobacteriaceae and Faecalibacterium prausnitzii were quantified using FISH. Correlations between urinary (52)Cr-EDTA excretion and other parameters were established using nonparametric Spearman’s correlation coefficients (ρ). RESULTS: CD patients with increased fecal calprotectin levels (> 100 μg/g) demonstrated an elevated urinary (52)Cr-EDTA/creatinine ratio (772 vs. 636 μmol/mol, P = 0.132). Patients with primarily colonic disease showed the highest (52)Cr-EDTA excretion. Importantly, a positive correlation was observed for the urinary (52)Cr-EDTA/creatinine ratio and fecal calprotectin levels (ρ = 0.325, P < 0.05). Finally, urinary (52)Cr-EDTA/creatinine ratio negatively correlated with the relative abundance of Faecalibacterium prausnitzii (ρ = -0.221, P = 0.092), while positively correlating with Enterobacteriaceae (ρ = 0.202, P = 0.126). CONCLUSIONS: Orally administered and renal excreted (52)Cr-EDTA may be used to assess intestinal permeability in CD and correlates with fecal calprotectin levels and bacterial species relevant to CD. This test may improve non-invasive detection of disease exacerbations and help monitor disease activity.
format Online
Article
Text
id pubmed-6366711
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63667112019-02-22 Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA von Martels, Julius Z. H. Bourgonje, Arno R. Harmsen, Hermie J. M. Faber, Klaas Nico Dijkstra, Gerard PLoS One Research Article BACKGROUND: Intestinal permeability can be assessed by monitoring renal excretion of orally administered radioactively (51)Cr-labeled ethylenediaminetetraacetic acid ((51)Cr-EDTA). Although considered safe, patient participation in using radio-labeled tracers is low. Here, we used orally administered (52)Cr-EDTA as non-radioactive alternative to assess intestinal permeability in CD and analyzed the association with disease activity, disease location and gut microbial dysbiosis. MATERIALS AND METHODS: 60 CD patients with low (n = 25) and increased (n = 35) fecal calprotectin levels (cut-off: 100 μg/g feces) ingested 20 mL (52)Cr-EDTA (20 mmol/L) solution whereafter 24-h urine was collected. Urinary (52)Cr-EDTA concentrations were quantified using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Fecal Enterobacteriaceae and Faecalibacterium prausnitzii were quantified using FISH. Correlations between urinary (52)Cr-EDTA excretion and other parameters were established using nonparametric Spearman’s correlation coefficients (ρ). RESULTS: CD patients with increased fecal calprotectin levels (> 100 μg/g) demonstrated an elevated urinary (52)Cr-EDTA/creatinine ratio (772 vs. 636 μmol/mol, P = 0.132). Patients with primarily colonic disease showed the highest (52)Cr-EDTA excretion. Importantly, a positive correlation was observed for the urinary (52)Cr-EDTA/creatinine ratio and fecal calprotectin levels (ρ = 0.325, P < 0.05). Finally, urinary (52)Cr-EDTA/creatinine ratio negatively correlated with the relative abundance of Faecalibacterium prausnitzii (ρ = -0.221, P = 0.092), while positively correlating with Enterobacteriaceae (ρ = 0.202, P = 0.126). CONCLUSIONS: Orally administered and renal excreted (52)Cr-EDTA may be used to assess intestinal permeability in CD and correlates with fecal calprotectin levels and bacterial species relevant to CD. This test may improve non-invasive detection of disease exacerbations and help monitor disease activity. Public Library of Science 2019-02-07 /pmc/articles/PMC6366711/ /pubmed/30730969 http://dx.doi.org/10.1371/journal.pone.0211973 Text en © 2019 von Martels et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
von Martels, Julius Z. H.
Bourgonje, Arno R.
Harmsen, Hermie J. M.
Faber, Klaas Nico
Dijkstra, Gerard
Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA
title Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA
title_full Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA
title_fullStr Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA
title_full_unstemmed Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA
title_short Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA
title_sort assessing intestinal permeability in crohn’s disease patients using orally administered (52)cr-edta
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366711/
https://www.ncbi.nlm.nih.gov/pubmed/30730969
http://dx.doi.org/10.1371/journal.pone.0211973
work_keys_str_mv AT vonmartelsjuliuszh assessingintestinalpermeabilityincrohnsdiseasepatientsusingorallyadministered52credta
AT bourgonjearnor assessingintestinalpermeabilityincrohnsdiseasepatientsusingorallyadministered52credta
AT harmsenhermiejm assessingintestinalpermeabilityincrohnsdiseasepatientsusingorallyadministered52credta
AT faberklaasnico assessingintestinalpermeabilityincrohnsdiseasepatientsusingorallyadministered52credta
AT dijkstragerard assessingintestinalpermeabilityincrohnsdiseasepatientsusingorallyadministered52credta